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RNA Sequencing of Human Peripheral
Nerve in Response to Injury: Distinctive
Analysis of the Nerve Repair Pathways
Andrew S. Welleford1,2,*, Jorge E. Quintero1,2,3,*, Nader El Seblani1,2,4,* ,
Eric Blalock1,2, Sumedha Gunewardena5, Steven M. Shapiro6,7,
Sean M. Riordan6, Peter Huettl1,2, Zain Guduru8, John A. Stanford7,
Craig G. van Horne1,2,3, and Greg A. Gerhardt1,2,3,8
Abstract
The development of regenerative therapies for central nervous system diseases can likely benefit from an understanding of the
peripheral nervous system repair process, particularly in identifying potential gene pathways involved in human nerve repair.
This study employed RNA sequencing (RNA-seq) technology to analyze the whole transcriptome profile of the human
peripheral nerve in response to an injury. The distal sural nerve was exposed, completely transected, and a 1 to 2 cm section of
nerve fascicles was collected for RNA-seq from six participants with Parkinson’s disease, ranging in age between 53 and 70 yr.
Two weeks after the initial injury, another section of the nerve fascicles of the distal and pre-degenerated stump of the nerve
was dissected and processed for RNA-seq studies. An initial analysis between the pre-lesion status and the postinjury gene
expression revealed 3,641 genes that were significantly differentially expressed. In addition, the results support a clear
transdifferentiation process that occurred by the end of the 2-wk postinjury. Gene ontology (GO) and hierarchical clustering
were used to identify the major signaling pathways affected by the injury. In contrast to previous nonclinical studies, important
changes were observed in molecular pathways related to antiapoptotic signaling, neurotrophic factor processes, cell motility,
and immune cell chemotactic signaling. The results of our current study provide new insights regarding the essential inter-
actions of different molecular pathways that drive neuronal repair and axonal regeneration in humans.
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Introduction
In contrast to the central nervous system (CNS), the axons of
the peripheral nervous system (PNS) are capable of regen-
erating after injury1 and re-establishing functional connec-
tions with their distal target2. This regeneration is enabled by
the interaction between the injured axons, the nerve extra-
cellular matrix, immune cells such as macrophages, and
Schwann cells3,4. These nerve components individually con-
tribute to peripheral nerve repair and interact with each other
to further support a functional regeneration5. Following an
injury to a peripheral nerve, the distal stump undergoes a
process known as Wallerian degeneration. Schwann cells,
macrophages, and neutrophils are the key players in this
process. Together they breakdown myelin debris and clear
the severed axonal membrane and cytoskeleton6. Repro-
grammed Schwann cells also communicate with the fibro-
blasts to synthesize major adhesion proteins and a new
extracellular matrix, which helps in bridging the proximal
and distal stumps of the injured nerve fibers (for review, see
Jessen and Mirsky8). Under favorable conditions, the prox-
imal segment of the injured axon sprouts new processes that
reassociate with a new phenotype of Schwann cells, opti-
mized for repair, and regenerate through the extracellular
matrix of the distal nerve. In this way, the regenerating per-
ipheral nerve fibers re-establish communication with the
original distal target and restore some degree of function.
Myelinating and nonmyelinating (Remak) subtypes of
Schwann cells undergo cellular reprogramming into a
“repair” profile in response to PNS injury7. Repair Schwann
cells shed their myelin, become mobile, and secrete trophic
factors and other signaling molecules to promote axonal
regeneration8. In response to an injury, Schwann cells
release soluble growth factors such as nerve growth factor,
brain-derived neurotrophic factor, insulin-like growth
factor-1, hepatocyte growth factor, vascular endothelial
growth factor, neurotrophin-3, and glial cell line-derived
neurotrophic factor (GDNF)9–12. These growth factors play
a crucial role in inducing and guiding the regenerating distal
end of the injured peripheral nerve fibers13.
Regulation of gene expression may be a therapeutic target
for promoting the successful recovery of peripheral nerve
after injury. Identification of those genes and how they inter-
act is crucial to exploring strategies that enhance the neural
protection, regeneration, and repair processes. Promoting
successful regeneration in the CNS has been difficult in
neurodegenerative diseases, traumatic brain injury, stroke,
epilepsy, and other neurological disorders. We believe that
understanding the gene expression changes that drive effec-
tive neural repair within the PNS may also help in identify-
ing new therapeutic targets or methods that could enhance
CNS neural regeneration.
Whole transcriptome profiling of gene expression in
response to peripheral nerve injury can now be feasibly
studied using RNA sequencing (RNA-seq) technology.
RNA-seq combines molecular biology approaches for RNA
amplification with bioinformatics tools for measuring and
validating large RNA-seq datasets. This technique allows for
quantitative measurements of thousands of gene transcripts
using small (10 to 30 mg or less) quantities of tissue. For a
review of the applications of RNA-seq see Han et al14.
Our study was conducted in conjunction with an ongoing
clinical trial (clinicaltrials.gov: NCT#02369003), the “DBS
Plus” trial, which involves grafting of autologous peripheral
nerve fascicles in patients with Parkinson’s disease (PD) at
the time of deep brain stimulation (DBS) surgery15, an
approach we call DPS Plus. To our knowledge, our study
is the first of its type studying and analyzing the human
peripheral nerve repair genetics in response to a transection
injury within the same human subjects. The central hypoth-
esis of this ongoing clinical trial is that the progression of
motor symptoms of PD may be slowed and modified by
providing a source of neuroprotective and pro-regenerative
factors, i.e., autologous peripheral nerve tissue, to the degen-
erating dopaminergic neurons responsible for the motor def-
icits of PD. The trial involved collection of two samples of
the sural nerve from the same participant at two distinct time
points. The first sample, referred to as the “pre-lesion” sam-
ple, was collected from the participant’s sural nerve during
Stage I of the surgery, which involved DBS hardware
implantation. The second sample, referred to as the “post-
lesion” sample, was taken 2 weeks later from the distal end
of the same nerve during Stage II of the surgery, which is the
stage when the DBS leads are positioned into the subthala-
mic nucleus (STN) or globus pallidus internus (GPi). This
two-stage approach corresponds with the two stages of DBS
surgery and was designed with the objective of inducing pro-
regenerative changes in the peripheral nerve following an
injury13,16. This current study was performed to analyze the
transcriptome profile of normal and transected sural nerve
tissue in patients with PD and to help evaluate how a con-




The nerve samples were collected from human subjects with
PD who electively consented to participate in the clinical
trial testing the safety and feasibility of peripheral nerve
grafts to the brain for the treatment of PD. The consent
allowed for the collection of sural nerve sample for research
studies. The nerve samples of six participants (two females
and four males), with a mean age of 64 þ 7 yr (mean +
standard deviation [SD]) (range 53 to 70 yr) and with a
diagnosed disease duration of 10 + 5 yr (range 2 to 16
yr), were used for RNA-seq analysis.
Tissue Collection
The sural nerve samples were collected at two different time
points: a pre-lesion sample was collected at the time of the
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first stage of DBS surgery (Stage I) followed by a post-lesion
sample from the second stage of DBS surgery (Stage II) 2
weeks later17,18 (Fig. 1). Both nerve samples were collected
before activating the DBS electrodes following the second
stage of DBS surgery. For the pre-lesion tissue collection,
the surgeon made a transverse incision through the skin of
the lateral ankle, 2 cm superior to the lateral malleolus. The
surgeon then identified the neurovascular bundle containing
the sural nerve with the associated artery and vein. The sural
nerve was then separated from the bundle using blunt dis-
section. Next, two black silk sutures were tied around the
nerve, roughly 1 cm apart, to mark the nerve. The section of
the sural nerve between these sutures was then cut, a 1-cm
nerve segment was removed, and the surgical area was
sutured and closed.
The removed section of nerve was then stripped of its
epineurium using microsurgical dissection in cold sterile sal-
ine. Individual fascicles of nerve fibers were separated using
jeweler’s forceps, and the perineurium was discarded (Fig. 1).
These fascicles were placed in conical microcentrifuge tubes,
snap-frozen on dry ice, and stored at 80C until they were
assayed. For post-lesion tissue collection, the surgical area
from Stage I was reopened at the original incision. The sur-
geon located the suture markers on the distal stump of the
transected sural nerve and removed a new 1 to 2 cm segment
of the remaining distal stump of the previously severed nerve.
The tissue was kept on sterile saline ice and was prepared for
the trial intervention as previously described17. Once the trial
intervention was completed, the remaining fascicles (Fig. 1B)
were placed in conical microcentrifuge tubes, snap-frozen on
dry ice, and stored at 80C until assayed.
RNA Extraction
RNA isolation was performed by homogenizing sural nerve
fascicles in 1 ml of TRI Reagent Solution (ThermoFisher
AM9738, USA) using a Fisher Scientific Power Gen 35
homogenizer (Fisher Scientific PG35-362, USA) with a
microtip homogenizing probe. The homogenized lysate was
transferred to a pre-pelleted 5Prime Phase Lock Gel—Heavy
2 ml tube (ThermoFisher NC1093153, USA) and incubated
at room temperature for 5 min. Two hundred microliters of
chloroform (Sigma-Aldrich C2432, USA) was added and the
tube was shaken vigorously by hand for 15 s. Phase separa-
tion was performed by microcentrifugation at 12,000 g for
10 min. The RNA containing aqueous phase was taken from
the top of the Phase Lock Gel layer and transferred to a 1.7-
ml microfuge tube. RNA was precipitated by adding 0.5 ml
isopropyl alcohol {2-Propanol} (Sigma-Aldrich I9516,
USA), mixed by repeated inversion, and incubated at room
temperature for 10 min. RNA was pelleted by microcentri-
fugation at 12,000  g for 10 min at 4C. RNA pellet was
washed two times with 80% ethanol (Sigma-Adrich E7023,
USA) using a 7,500 g microcentrifugation for 5 min at 4C
to pellet RNA between washes. RNA pellets were air dried 5
to 10 min at room temperature and resuspended in 25 ml of
nuclease-free water. RNA purity was assessed by OD260/
OD280 ratio calculation using a ThermoFisher NanoDrop
1000 Spectrophotometer (ThermoFisher ND-1000, USA).
RNA Integrity was assessed by Agilent Bioanalyzer 2100
(Agilent G2939BA, USA) using the Eukaryotic Total RNA
Nano assay.
RNA Sequencing
RNA-Seq was performed at a strand-specific 100 cycle
paired-end resolution, in an illumina HiSeq 2500 sequencing
machine (Illumina, San Diego, CA, USA). In a repeated
measure design, mRNA from the six individual samples
were sequenced pre- and post-lesioning, thus, resulting in a
total of 12 samples. The 12 samples were multiplexed in two
lanes of a flow cell, resulting between 25 and 34 million
Fig. 1. Photographs of the peripheral nerve fascicles analyzed in this study. (A) The samples collected in Stage I of the DBS surgery (pre-
lesion sample). (B) The samples collected in Stage II of the DBS surgery (post-lesion sample). DBS: deep brain stimulation.
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reads per sample. The read quality was assessed using the
FastQC software19. On average, the per sequence quality
score measured in the Phred quality scale was above 30 for
all the samples. The reads were mapped to the human gen-
ome (GRCh38) using the STAR software, version 2.3.1z20.
On average, 96.4% of the sequenced reads mapped to the
genome, resulting between 24.3 and 32.8 million mapped
reads per sample, of which on average 89% were uniquely
mapped reads. Transcript abundance estimates were calcu-
lated using HTSeq (version 0.6.1)21. Expression normaliza-
tion and differential gene expression calculations were
performed in edgeR (release 2.14)22 to identify statistically
significant differentially expressed genes. A paired sample
design was used in edgeR, which employs a negative bino-
mial generalized linear model for statistical calculations.
The edgeR package implements advanced empirical Bayes
methods to estimate gene-specific biological variation under
minimal levels of biological replication. The RNA composi-
tion in each sample was normalized in edgeR using the
trimmed mean of M-values method. The significant P-values
were adjusted for multiple hypotheses testing by the Benja-
mini and Hochberg method23 as modified by Storey24, pro-
viding a false discovery rate q value for each differentially
expressed gene. Genes with an absolute fold difference 2
and q  0.05 were considered statistically significant.
RNA-Seq Analysis
RNA-seq data were organized in a Microsoft Excel table for
subsequent analyses. These normalized read counts (counts
per million) were used to calculate fold change between the
pre-lesion and post-lesion samples, and the log base 2 of fold
change was used for further analysis.
Correlation matrices and heat maps, as well as volcano
plots, were generated in Excel. Functional overrepresenta-
tion analysis on the GO set of term annotations25 was per-
formed using DAVID pathway analysis26. DAVID is an
online software tool that groups genes based on their func-
tional similarity. Given a list of significantly differentially
expressed genes, DAVID uses a fuzzy clustering algorithm,
that uses information in its knowledge base on genes and
their functional associations, to group genes that are
together, statistically significant in their association to a set
of common functional categories26.
AmiGO GO annotations (http://www.geneontology.org/)
for terms of interest were cross-referenced with significantly
differentially expressed genes, yielding a list of differentially
expressed genes related to each GO annotation’s respective
biological function. The GO annotations chosen to be visua-
lized in heat maps were selected based on their relevance to
peripheral nerve repair16. Statistical criteria of q  0.05 and
|FC| 2 were selected, yielding a total of 3,641 differentially
expressed genes included in this analysis. Heat maps of the
qualifying genes were generated using JMP Pro 13 (SAS).




The mass and freezing delay time (time from when the nerve
was removed from participant to when it was snap-frozen in
dry ice) were calculated for the pre-lesion and post-lesion
tissue (Table 1). Freezing time delay was significantly lon-
ger (paired two tailed t-test: t(5) ¼ 4.863, P ¼ 0.004) for
post-lesion nerve samples (59 + 25 min; mean + SD) than
pre-lesion ones (18 + 5 min). This difference was a result of
the longer surgical procedures needed for Stage II of the
DBS surgery. The mitigation of Mass Effect during the RNA
Access library preparation was accomplished in multiple
ways through normalizations incorporated at multiple steps
through the entire process of library preparation and
sequencing.
Correlation Matrix and Volcano Plot
Analysis of the samples showed statistically significant
changes in RNA levels among all six participants in response
to the nerve transection lesion (Fig. 2A), with significant
differences between the pre- and post-lesion samples and
similarities within each of these groups as assessed by Pear-
son r correlation.
Table 1. Mass and Freezing Time Delay of the Nerve Samples Collected During Stage I vs Stage II.
Stage I samples Stage II samples
Participant Mass (g) Freezing time delay (min) Mass (g) Freezing time delay (min)
1 0.0205 16 0.0354 41
2 0.0158 28 0.0301 108
3 0.0254 20 0.0613 64
4 0.0256 14 0.0363 52
5 0.0294 14 0.0757 39
6 0.0197 17 0.0256 50
Mean + SD 0.0227 + 0.0049 18 + 5 0.0441 + 0.0198 59 + 25
Freezing time delay includes the gross dissection time during which fascicles were separated from the whole nerve and the time required for fascicle segment
grafting into participants during Stage II. SD: standard deviation.
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The Volcano plot (Fig. 2B) estimates the most meaningful
changes in the gene transcriptome, between pre- and post-
lesion that exceeded a cutoff of q  0.0003 and fold change
|FC| 4. Of those significantly differentially expressed genes,
693 gene transcripts (orange) were increased and 576 gene
transcripts were decreased (blue). This analysis demonstrates
that even with a very conservative criterion, there were hun-
dreds of differentially expressed genes between the pre- and
post-lesion tissue samples.
DAVID Pathway Analysis
DAVID pathway analysis revealed that the majority of the
most significantly upregulated pathways (Table 2) were
related to cell cycle, cell proliferation, and immune cell
function. The majority of the most significantly downregu-
lated pathways (Table 3) were related to synaptic structure
and neuron function.
Growth Factor Activity
Figure 3 shows all significantly differentially expressed (q <
0.05, |FC| > 2) gene transcripts annotated with the Gene
Ontology (GO) term “Growth Factor Activity”
(GO:0008083). Out of 166 unique genes with this GO anno-
tation, 43 (25.9%) were significantly differentially expressed
between pre- and post-lesion. Twenty-six of those genes
were more abundant, whereas 17 genes were less abundant
in post-lesion tissue in comparison with pre-lesioning levels.
Myelination
Figure 4 shows all significantly differentially expressed (q <
0.05, |FC| > 2) gene transcripts annotated with the GO term
“Myelination” (GO:0042552). Out of 110 unique genes with
this GO annotation, 48 genes (43.6%) were significantly
differentially expressed. Seven genes were more abundant
and 41 genes were less abundant in response to the injury.
Schwann Cell Transdifferentiation
Using the GO term “Epithelial–Mesenchymal Transition”
(GO:0001837), 130 unique genes were yielded (Fig. 5). Of
these, 29 genes (22.3%) were significantly differentially
expressed (24 genes were more abundant and 5 genes were
less abundant in post-lesion samples than pre-lesion samples).
Likewise, the GO term “Schwann Cell Differentiation”
(GO:0014037) identified 36 unique genes. Of these genes,
15 (41.7%) were significantly differentially expressed, with
only 1 gene being more abundant while the other 14 genes less
abundant in Stage II samples than Stage I samples.
Neuroprotection
“Negative Regulation of Apoptotic Processes” is defined by
“Any process that stops, prevents, or reduces the frequency,
rate or extent of cell death by apoptotic process.” And Neg-
ative Regulation of Neuron Death is defined as “any process
that stops, prevents or reduces the frequency, rate or extent
of neuron death.” Figure 6 shows all significantly differen-
tially expressed gene transcripts annotated with the GO term
“Negative Regulation of Apoptotic Processes”
(GO:0043066) or “Negative Regulation of Neuron Death”
(GO:1901215). This ontology yielded 916 unique genes, of
which 128 (14.0%) were significantly differentially
expressed (all 128 genes were more abundant in Stage II
samples than in Stage I samples). Meanwhile, for Negative
Regulation of Neuron Death, we found 67 genes out of 206
(32.5%) were significantly differentially expressed (45
genes more abundant and 22 genes less abundant in post-
lesion samples than in pre-lesion samples). These gene
changes indicated significant increases in transcripts of
genes related to the reduction of neuron death.
Fig. 2. (A) Correlation matrix or Pearson’s r for the transcriptional profile of every subject vs every other subject. Scale bar: Correlation
values range from 0.4 (blue—less similar) to 1 (red—more similar). This visualization shows strong agreement among different profiles
within each stage, and a sharp distinction between stages. (B) Differences between Stage 1 and Stage 2. Log 2 scale fold changes (x-axis) are
plotted as a function of P-value (inverted log 10 scale—volcano plot). Results that exceed conservative q-value (q  0.0003) and fold change
(|FC|  4) cutoffs are highlighted (blue—downregulated in Stage 2, red—upregulated in Stage 2). FC: fold change.
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Discussion
These results provide evidence that the transection lesion
paradigm used in these surgeries induces phenotypic
changes in the peripheral nerve tissue consistent with the
peripheral nerve repair response: immune cell infiltration
plus cell proliferation, Wallerian degeneration of axons, ces-
sation of myelin synthesis, and upregulation of growth fac-
tors production16,27,28. DAVID pathway analysis revealed
significant changes in genes related to the cell cycle, cell
proliferation, immune cell function, synaptic structure, and
Table 3. Top Significantly Decreased Gene Ontology (GO) Pathways During Regeneration.
GO ID GO term Number of gene transcripts P-value
GO:0042391 Regulation of membrane potential 17 2.69E-08
GO:0098590 Plasma membrane region 27 4.06E-08
GO:0050803 Regulation of synapse structure or activity 14 8.01E-08
GO:0050877 Neurological system process 22 7.00E-07
GO:0050808 Synapse organization 13 8.20E-07
GO:0048812 Neuron projection morphogenesis 18 4.23E-06
GO:0030426 Growth cone 10 1.42E-05
GO:0050807 Regulation of synapse organization 8 4.21E-05
GO:0034765 Regulation of ion transmembrane transport 13 5.56E-05
GO:0005578 Proteinaceous extracellular matrix 13 6.25E-05
GO:0035725 Sodium ion transmembrane transport 8 7.87E-05
GO:0098794 Postsynapse 13 9.39E-05
Table 2. Top Significantly Increased Gene Ontology (GO) Pathways During Regeneration.
GO ID GO term Number of gene transcripts P-value
GO:0000278 Mitotic cell cycle 83 2.42E-32
GO:0007067 Mitotic nuclear division 57 3.97E-31
GO:0000819 Sister chromatid segregation 41 1.20E-27
GO:0044770 Cell cycle phase transition 49 4.75E-19
GO:0071103 DNA conformation change 32 1.21E-16
GO:0002682 Regulation of immune system process 62 4.67E-14
GO:0000228 Nuclear chromosome 41 3.38E-13
GO:0006952 Defense response 58 1.11E-11
GO:1901987 Regulation of cell cycle phase transition 29 5.00E-11
GO:0051303 Establishment of chromosome localization 14 2.42E-10
GO:0006259 DNA metabolic process 46 4.49E-09
GO:0002366 Leukocyte activation involved in immune response 19 6.52E-09
GO:0042129 Regulation of T cell proliferation 16 1.64E-08
GO:0051321 Meiotic cell cycle 17 2.41E-07
GO:0006342 Chromatin silencing 13 5.18E-07
GO:0033043 Regulation of organelle organization 46 5.84E-07
GO:0032640 Tumor necrosis factor production 12 7.16E-07
GO:0000910 Cytokinesis 13 1.42E-06
GO:0046631 Alpha-beta T cell activation 12 2.69E-06
GO:0001932 Regulation of protein phosphorylation 45 3.85E-06
GO:0006302 Double-strand break repair 16 6.15E-06
GO:0007051 Spindle organization 12 1.01E-05
GO:0050663 Cytokine secretion 13 1.54E-05
GO:0032101 Regulation of response to external stimulus 28 2.78E-05
GO:0032675 Regulation of interleukin-6 production 10 2.86E-05
GO:0019899 Enzyme binding 54 3.65E-05
GO:0060089 Molecular transducer activity 35 3.80E-05
GO:0044774 Mitotic DNA integrity checkpoint 11 5.42E-05
GO:0006270 DNA replication initiation 7 5.53E-05
GO:0002704 Negative regulation of leukocyte-mediated immunity 7 6.60E-05
GO:0032760 Positive regulation of tumor necrosis factor production 8 7.62E-05
GO:0034501 Protein localization to kinetochore 5 8.20E-05
GO:0009897 External side of plasma membrane 14 8.27E-05
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neuron function. In addition, significant decreases in
myelination-related gene transcripts were observed. The
majority of significantly differentially expressed genes
related to growth factor activity were upregulated, and of
particular note was the expression of the GDNF gene. GDNF
is known to promote neuroprotection and/or neurorestora-
tion in the CNS and has been studied as a therapeutic for
PD, reaching Phase I and II clinical trials in humans29–31.
These results also demonstrated a loss of markers of mature
Schwann cell phenotype (MYOC32, FA2H33) while those of
the epithelial–mesenchymal transition increased (SNAI234,
WNT235). Taken together, these results indicate that the
transection injury paradigm used in these human surgeries
induced the transdifferentiation or reprogramming of periph-
eral nerve Schwann cells from a mature (myelinating) form
into a repair (demyelinating) phenotype.
To better refine the results of our RNA-seq analysis to a
more “biologically relevant” dataset, we decided to limit our
observations to the genes whose transcript levels exceeded a
fold change threshold of |FC| > 2. However, this convention
may exclude genes that are biologically relevant at lower
fold changes. For example, the transcription of NF2 gene,
a marker of Schwann cell proliferation, was statistically sig-
nificantly increased (P-value ¼ 0.0192). However, the fold
Fig. 3. Heat map showing all significantly differentially expressed (q
< 0.05, |FC| > 2) gene transcripts annotated with the GO term
“Growth factor Activity” (GO:0008083). Genes are organized by
Ward hierarchical clustering. Dendrograms are scaled to hierarch-
ical clustering distance; longer branches represent more distant
clusters. FC: fold change; GO: gene ontology.
Fig. 4. Heat map showing all significantly differentially expressed (q
< 0.05, |FC| > 2) gene transcripts annotated with the GO term
“Myelination” (GO:0042552). Genes are organized by Ward hier-
archical clustering. Dendrograms are scaled to hierarchical cluster-
ing distance; longer branches represent more distant clusters. FC:
fold change; GO: gene ontology.
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change of transcript levels was less than 2, so it was not
included in the visualized data. Likewise, Mesencephalic
Astrocyte Derived Neurotrophic Factor (MANF) transcripts
level was significantly higher postinjury (P-value ¼ 3.03E-
07), yet its FC was 1.754 (data not shown). MANF plays a
vital role in different reparative phases during the neuronal
regeneration processes36, and MANF therapeutics are
expected to enter clinical trials. Furthermore, we focused
in this article only on transcripts that were differentially
expressed between pre- and post-lesion samples while
recognizing that some genes could be highly expressed in
both stages, but not necessarily differentially. This is one
limitation of this broad analysis approach, and in the specific
case of NF2 levels in this tissue merits further study. The
visualization of the negative regulation of apoptotic pro-
cesses was also striking because over 100 genes were signif-
icantly differentially expressed and all were upregulated.
This suggests that marked suppression of apoptosis was
occurring in this tissue. Whether these antiapoptotic pro-
cesses confer neuroprotection after tissue grafting merits
further study.
The gene cluster of the growth factor terms showed mul-
tiple differentially expressed genes, with the majority being
increased. One increased gene of note is GDNF, which is
neuroprotective and neurorestorative of dopaminergic neu-
rons and has been tried as a therapeutic intervention for
PD29,31,37,38. All post-lesion nerve samples, except one,
demonstrated an upregulation of GDNF transcription. Only
the nerve sample collected from participant number 2
demonstrated a lower number of GDNF transcripts after
injury (Fig. 3). The significant longer freezing time delay
for this sample (Table 1) might have negatively affected
GDNF-mRNA stability and its relevant count during RNA-
seq processing. Multiple interleukins were also upregulated
which, in addition to being cytokines, play a role in neuro-
genesis (for review, see Borsini et al39). For example, the
levels of gene transcript for IL-6, which has been described
as neuroprotective against focal brain injury, were increased
in response to the nerve injury40. The growth factor activity
genes, which were decreased (e.g., CDNF) at 2 weeks post-
injury are also of interest and may indicate the complexity of
the neuronal repair process in regard to the changes of indi-
vidual growth factors over time in response to nerve injury.
That was evident in the work of Lin et al41 as PPAR, PI3K-
Akt, and chemokine signaling pathways were dominant in
early Wallerian degeneration. Whereas at the later stage, the
main signaling pathways were ErbB, tumor necrosis factor,
AMPK, MAPK, PPAR, and Wnt41.
To our knowledge only Weiss and colleagues42 have per-
formed RNA-seq analysis on human peripheral nerve fasci-
cles. They studied human peripheral nerve fascicles
collected during surgeries, ex vivo degenerated nerves (for
8 d), cultured Schwann cells, and cultured fibroblasts. Their
method of obtaining degenerated nerves differed from ours
in that our model was degenerated in vivo and tissues were
collected 2 weeks postinjury. Studies in animal models are
more common. Arthur-Farraj et al28 reported transcriptome
and DNA methylome findings from mouse models. They
found changes in epithelial–mesenchymal transition, which
we also observed. Yi et al43 studied a rat model of sciatic
nerve crush injury and showed at acute, subacute, and post-
acute time points the expression of inflammation and
immune response; cellular movement, development, and
morphology; and lipid metabolism, cytoskeleton reorganiza-
tion, and nerve regeneration were all upregulated, respec-
tively. Of note both Arthur-Farraj et al. and Yi et al.
Fig. 5. Heat map showing all significantly differentially expressed (q
< 0.05, |FC| > 2) gene transcripts annotated with the GO term
“Epithelial–Mesenchymal Transition” (GO:0001837) or “Schwann
Cell Differentiation” (GO:0014037). Genes are organized by Ward
hierarchical clustering. Dendrograms are scaled to hierarchical
clustering distance; longer branches represent more distant clus-
ters. FC: fold change; GO: gene ontology.
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performed sequencing at multiple time points postinjury.
This approach allowed them to show the change in differen-
tially expressed pathways over time.
Myelination genes showed that significantly differen-
tially expressed genes of this ontology were decreased 2
weeks after injury. This is consistent with myelin
Fig. 6. Heat map showing all significantly differentially expressed (q < 0.05, |FC| > 2) gene transcripts annotated with the GO term “Negative
Regulation of Apoptotic Processes” (GO:0043066) or “Negative Regulation of Neuron Death (GO:1901215).” Genes are organized by
Ward hierarchical clustering. Dendrograms are scaled to hierarchical clustering distance; longer branches represent more distant clusters.
FC: fold change; GO: gene ontology.
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degradation after peripheral nerve injury as previously
described44. In general, the Schwann cells showed overall
decreased transcripts related to differentiation. This could be
interpreted as transdifferentiation or reprogramming of
Schwann cells27. However, this comparison was not straight-
forward. We expected to see that the JUN gene, which codes
for the c-Jun transcription factor that regulates Schwann cell
transdifferentiation, would be increased27. We found that the
JUN gene was not significantly differentially expressed in
these samples. We currently hypothesize that the time course
of JUN transcription did not match with the two samples
taken 2 weeks apart, as previous studies have identified
increased JUN levels at 1 week post-lesion28. In fact, this
study is limited overall in that it only addresses the levels of
gene transcripts in the fascicles 2 weeks after the injury.
Ideally, future studies should strive to investigate both
shorter (3 to 7 days) and longer (3 to 6 weeks) postinjury
periods to better understand the transdifferentiation process
and the time course of the repair code.
The participants who donated tissue for this study had all
been diagnosed with idiopathic PD and it is possible that the
disease processes of this neurodegenerative disorder had
some effect on peripheral nerve gene expression and its
injury response, though this is not described in the available
scientific literature. In other participants of the clinical trial
(not included here), who have had a history of neuropathy,
we have used clinical nerve conduction velocity tests to
assess the sural nerve before grafting. None of those partici-
pants showed remarkable decrements in nerve conduction
velocity (data not shown). A future study comparing baseline
levels of RNA in patients with PD versus age-matched
healthy controls could help determine potential baseline
differences.
Because the underlying clinical trial necessitates a full
transection of the sural nerve and excision of approximately
3 to 5 cm, participants commonly reported a painful sensa-
tion immediately postoperatively followed by numbness or
tingling on the lateral aspect of the ankle and/or foot even
after 1 yr. However, participants have not reported the sen-
sation as painful or bothersome. The use of sural nerve exci-
sion in neurosurgical and plastic surgery applications has a
robust literature and is shown to be well tolerated45,46.
With regard to the influence of variation of age and
degree of PD within the study group, there was a remarkable
consistency of transcriptome profiles within the pre- and
post-lesion groups as assessed by the Pearson r correlation.
The transcriptome profile of all participants in the pre-lesion
group was similar, as was the transcriptome profile of all
participants in the post-lesion group. The histology and tran-
scriptome profiles of the peripheral nerve tissue in response
to an injury were consistent with previous reports28,42,43.
Furthermore, the correlation matrix visualizes the consistent
RNA levels between participants as a result of the pre-
lesioning approach15,17. These results support consistent
transcriptome changes within the study group. Furthermore,
these results support the feasibility and reproducibility of the
time delayed approach for producing transdifferentiation of
the sural nerve tissue into a repair cell phenotype in subjects
with PD.
The freezing time delay difference between pre- and post-
lesion samples is one of the limitations with the design of our
study. This was inherent to the trial design where the focus
was to optimize the surgical grafting procedure and the
availability of tissue to be grafted during the DBS surgery.
In Stage I the tissue was processed to isolate the fascicles
immediately after extraction. During Stage II, the fascicles
were removed from the sural nerve tissue, placed on saline
ice, the sural nerve incision was closed, the graft locations in
the brain were targeted, and the fascicle tissue was then
grafted into the patient. We recognize that this delay was
reflected in the difference in freezing time between the
stages and it added to the variability between the samples.
As a result, some of the transcriptome measurements might
have been affected especially in the post-lesion samples
compared to the in vivo state. Additionally, this analysis of
peripheral nerve repair is in the context of a full transection
injury. Other injury modalities, e.g., crush injuries, have
been shown to induce different repair processes than trans-
ection injury47. One key difference is that while both crush
and transection injury lead to Wallerian degeneration distal
to the injury, in a crush injury the extracellular matrix scaf-
fold remains intact, while this scaffold is interrupted in trans-
ection injury48. This should be considered when applying
these findings to other injury models.
The sural nerve fascicles analyzed by RNA-seq included
all cells and tissue components within the peripheral nerve. It
should be noted that the tissue analyzed does not include the
epineurium of the sural nerve. This was intentional, as it
reflects the graft tissue composition (fascicles only), which
is intended to contain mostly Schwann cells, macrophages,
and extracellular matrix. This yielded an aggregate of all
RNA in the tissue from multiple cell types. A future study
using single-cell RNA-seq would be able to investigate the
responses of individual peripheral nerve cells and cell types.
Thus, it is possible that while we have emphasized the
importance of the Schwann cells in the RNA-seq data and
the “repair cell” properties of the tissue that the results can-
not at this time be solely attributed to changes in Schwann
cells. Furthermore, while Weiss et al. validated RNA-seq
information using proteomics, this study focused on tran-
scriptome changes in the peripheral nerve in response to
injury but did not assess protein changes. Future studies
could shed additional light as to the in vivo response of
peripheral nerve in response to injury as well as the relation-
ship of the transcriptome to the proteome of this dynamic
tissue.
Taken together, the results of this study present whole-
tissue transcriptome-scale data about the Wallerian degen-
eration affecting the distal stump of human peripheral nerve
and at 2 weeks postinjury. The findings of this study reveal
significant changes in the transcriptome of an injured human
peripheral nerve after 2 weeks of repair processes in situ.
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Finally, this study provides data for future researchers to
analyze and incorporate within their bioinformatics models
of Wallerian degeneration. Such models may strengthen our
understanding of the peripheral nerve repair process and its
relevance to basic science as well as clinical and transla-
tional research that are looking to adapt peripheral nerve
tissue/cells for use in promoting neuroprotection, neural
repair, and regeneration for disorders of the CNS.
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